Glucocorticoids, inflammation and the perinatal lung.
Glucocorticoids, inflammation and the perinatal lung.
复制标题
DOI：
10.1053/siny.2001.0068
复制
发表时间：
2001-08-01
期刊：
影响因子：
--
通讯作者：
Jobe, A H
中科院分区：
文献类型：
--
作者：
Jobe, A H
许多孕妇在孕30周以下分娩早产儿时患有亚临床绒毛膜炎。根据现行指南，给予母体糖皮质激素治疗以诱导肺成熟。胎儿暴露于炎症前体可引起急性和慢性损伤，但炎症也可诱导胎肺成熟。产前糖皮质激素和炎症都通过诱导表面活性剂系统、诱导结构成熟和抑制肺泡形成来调节肺发育。未来的机会是开发新的更安全的策略来使早产胎儿成熟，风险是重复糖皮质激素暴露和未识别的胎儿暴露于炎症的潜在不良相互作用。
Many women delivering preterm infants at less than 30 weeks gestation have subclinical chorioamnionitis. Based on current guidelines, maternal glucocorticoid treatment is given to induce lung maturation. Fetal exposure to proinflammation can cause acute and chronic injury, but inflammation also can induce fetal lung maturation. Both antenatal glucocorticoids and inflammation modulate lung development, by inducing the surfactant system, inducing structural maturation, and inhibiting alveolarization. The opportunities for the future are to develop new safer strategies to mature the preterm foetus, and the risks are potential adverse interactions of repetitive glucocorticoid exposures and unrecognized fetal exposure to inflammation.